The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1076
April 17, 2000
View Complete Issue         Table of Contents 2019 
Exemestane For Advanced Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Exemestane For Advanced Breast Cancer
April 17, 2000 (Issue: 1076)
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Exemestane For Advanced Breast Cancer
Article code: 1076b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.